Enfermedad de injerto cutáneo contra huésped

-A A +A
Artículo de revisión
Rev Asoc Colomb Dermatol. 2016; 24: 2 (Abril-Junio), 90-102.

Enfermedad de injerto cutáneo contra huésped

Cutaneous graft versus host disease
Autor(es): 
Claudia Liliana Montoya
gabclau@outlook.com
Médica dermatóloga, Fundación Valle de Lili, Cali, Colombia.
Melibea Sierra
Médica interna, Universidad Icesi-Fundación Valle de Lili, Cali, Colombia.
Andrés Vidal
Médico dermatólogo; jefe de posgrado en Dermatología, Universidad Icesi-Fundación Valle de Lili, Cali, Colombia.
Resumen: 

El trasplante de células hematopoyéticas es un tratamiento potencialmente curativo para enfermedades hematológicas neoplásicas o no neoplásicas, en el cual se administra quimioterapia condicionante, radioterapia o ambas, para tratar la enfermedad de base y ocasionar una supresión inmunitaria que prevenga el rechazo del injerto. Posteriormente, se hace una infusión en el receptor de células hematopoyéticas progenitoras derivadas de médula ósea, sangre periférica o sangre de cordón umbilical. La piel se afecta en el 81 % de los pacientes, constituyéndose en el órgano más frecuentemente comprometido y ocasionando una heterogeneidad de lesiones clínicas a las cuales el dermatólogo debe enfrentarse; su diagnóstico y tratamiento son, en muchas ocasiones, un reto.

Palabras clave: 
trasplante células hematopoyéticas, injerto contra huésped, manifestaciones cutáneas, tolerancia inmunitaria.

Summary: 

Hematopoietic stem cell transplantation is a potentially curative therapy for hematologic neoplastic or non-neoplastic diseases, in which a conditioning chemotherapy and/or radiation therapy are given to treat the underlying disease and cause immune suppression to prevent graft rejection, and then infusing in the receptor, hematopoietic progenitor cells derived from bone marrow, peripheral blood or cord blood. The skin is affected in 81 % of patients, becoming the organ most frequently compromised and causing heterogeneity of clinical lesions to which the dermatologist must face, being often a challenge to diagnosis and treatment.

Key words: 
Hematopoietic stem cell transplantation, cutaneous graft versus host disease, immune tolerance.
PDF del articulo
AsoColDerma
AsoColDerma
Enfermedad de injerto cutáneo contra huésped
Enfermedad de injerto cutáneo contra huésped

Referencias

  1. Pasquini M, Wang Z, Horowitz MM, Gale RP. 2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): Current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl. 2013;187-97.
  2. Enfermedad injerto contra huésped en el trasplante hematopoyético. Piel. 2004;19:431-41. Fecha de consulta: 16 de febrero de 2015. Disponible en: http://www.carmenbrufau.es/images/EICH.pdf.
  3. Hymes SR, Alousi AM, Cowen EW. Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol. 2012;66:515.e1-18.
  4. Peñas PF, Zaman S. Many faces of graft-versus-host disease. Australas J Dermatol. 2010;51:1-10.
  5. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966-1967;62:21-78.
  6. Jagasia M, Giglia J, Chinratanalab W, Dixon S, Chen H, Frangoul H, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant. 2007;13:1207-15. Fecha de consulta: 16 de febrero de 2015. http://www.bbmt.org/article/S1083-8791(07)00338-2/pdf.
  7. Flowers MED, Inamoto Y, Carpenter PA, Lee SJ, Kiem H-P, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214-9. Fecha de consulta: 16 de febrero de 2015. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062319/.
  8. Vigorito AC, Campregher P V, Storer BE, Carpenter PA, Moravec CK, Kiem H-P, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009;114:702-8. Fecha de consulta: 16 de febrero de 2015. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713471/.
  9. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945-55. Fecha de consulta: 19 de septiembre de 2014. Disponible en: http://www.bbmt.org/article/S1083-8791(05)00631-2/pdf.
  10. Velásquez M. Enfermedad injerto contra huésped. Rev Asoc Colomb Alerg Asma Inmunol. 2001;10:110-9.
  11. Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. Orphanet J Rare Dis. 2007;2-35. Fecha de consulta: 7 de enero de 2015. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2018687/.
  12. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15:1767-77. Fecha de consulta: 16 de febrero de 2015. Disponible en: http://web.b.ebscohost.com.bdigital.ces.edu.co:2048/ehost/pdfviewer/pdfv....
  13. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Eng J Med. 1985:313:765-71.
  14. Murashige N, Kami M, Mori SI, Katayama Y, Kobayashi K, Onishi Y, et al. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor. Am J Hematol. 2008;83:630-4.
  15. Flomenberg N, Baxter-Lowe LA, Confer D, Fernández-Vina M, Filipovich A, Horowitz M, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104:1923-30. Fecha de consulta: 16 de febrero de 2015. Disponible en: http://www.bloodjournal.org/content/104/7/1923.long?sso-checked=true.
  16. Petersdorf EW, Kollman C, Hurley CK, Dupont B, Nademanee A, Begovich AB, et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: The US National Marrow Donor Program Experience. Blood. 2001;98:2922-9. Fecha de consulta: 20 de febrero de 2015. Disponible en: http://www.bloodjournal.org/content/98/10/2922.long.
  17. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-8.
  18. Shulman HM, Cardona DM, Greenson JK, Hingorani S, Horn T, Huber E, et al. NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant. 2015;21:589-603. Fecha de consulta: 22 de julio de 2015. Disponible en: http://www-ncbi-nlm-nih-gov.bdigital.ces.edu.co:2048/pmc/articles/PMC435....
  19. Imanguli M, Alevizos I, Brown R, Pavletic S, Atkinson J. Oral graft-versus-host disease. Oral Dis. 2008;14:396-412. Fecha de consulta: 3 de marzo de 2015. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2565862/.
  20. Vargas-Díez E, García-Díez A, Marín A, Fernández-Herrera J. Life-threatening graft-vs-host disease. Clin Dermatol. 2005;23:285-300.
  21. Levy-Polack MP, Sebelli P, Polack NL. Incidence of oral complications and application of a preventive protocol in children with acute leukemia. Spec Care Dentist.1998;18:189-93.
  22. Reyes AD, Martín TA, Leache EB, Suárez C. Manifestaciones orales en la enfermedad injerto contra huésped (EICH). Presentación de un caso. Med Oral. 2003;8: 361-5. Fecha de consulta: 5 de febrero de 2016. Disponible en: http://www.medicinaoral.com/pubmed/medoralv8_i5_p361.pdf.
  23. Mays JW, Fassil H, Edwards DA, Pavletic SZ, Bassim CW. Oral chronic graft-versus-host disease: Current pathogenesis, therapy, and research. Oral Dis. 2013;19:327-46. Fecha de consulta: 5 de febrero de 2016. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561479/?tool=pmcentrez.
  24. Mays SR, Kunishige JH, Truong E, Kontoyiannis DP, Hymes SR. Approach to the morbilliform eruption in the hematopoietic transplant patient. Semin Cutan Med Surg. 2007;26:155-62.
  25. Lützow-Holm C, Rønnevig JR. Cutaneous drug reactions. Tidsskr Nor Laegeforen. 2005;125:2483-7.
  26. Byun HJ, Yang JI, Kim BK, Cho KH. Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions. J Am Acad Dermatol. 2011;65:726-32.
  27. Horn TD, Redd J V, Karp JE, Beschorner WE, Burke PJ, Hood AF. Cutaneous eruptions of lymphocyte recovery. Arch Dermatol. 1989;125:1512-7.
  28. Martín PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: Recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150-63. Fecha de consulta: 10 de marzo de 2015. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404151/.
  29. Hymes SR, Alousi AM, Cowen EW. Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease. J Am Acad Dermatol. 2012;66:535.e1-16.
  30. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303-14. Fecha de consulta: 10 de marzo de 2015. Disponible en: http://www.bloodjournal.org/content/92/7/2303.long?sso-checked=true.
  31. Klassen J. The role of photopheresis in the treatment of graft-versus-host disease. Curr Oncol. 2010;17:55-8.
  32. Calore E, Marson P, Pillon M, Tumino M, Tison T, Mainardi C, et al. Treatment of acute GVHD in childhood with extracorporeal photochemotherapy/phofotopheresis: The Padova experience. Biol Blood Marrow Transplant. 2015;21:1963-72.
  33. Greinix HT, Worel N, Just U, Knobler R. Extracorporeal photopheresis in acute and chronic graft-versus-host disease. Transfus Apher Sci. 2014;50:349-57. Fecha de consulta: 25 de julio de 2015. Disponible en: https://www-clinicalkey-com.bdigital.ces.edu.co:2443/service/content/pdf....
  34. Gómez-Almaguer D, Ruiz-Argüelles GJ, del Carmen Tarín-Arzaga L, González-Llano O, Gutiérrez-Aguirre H, Cantú-Rodríguez O, et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14:10-5.
  35. Teshima T, Maeda Y, Ozaki K. Regulatory T cells and IL-17-producing cells in graft-versus-host disease. Immunotherapy. 2011;3:833-52.
  36. Pidala J, Anasetti C. Glucocorticoid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:1504-18. Disponible en: http://www.bbmt.org/article/S1083-8791(10)00012-1/pdf.
  37. Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215-33.
  38. Horwitz ME, Sullivan KM. Chronic graft-versus-host disease. Blood Reviews. 2006;20:15-27.
  39. Wojnar J, Giebel S, Holowiecka-Goral A, Krawczyk-Kulis M, Markiewicz M, Wozniczka K, et al. The incidence and risk factors for chronic graft-versus-host-disease. Ann Transplant. 2006;11:14-20.
  40. Storb R, Prentice RL, Sullivan KM, Shulman HM, Deeg HJ, Doney KC, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98:461-6. Fecha de consulta: 22 de febrero de 2015. Disponible en: http://web.a.ebscohost.com.bdigital.ces.edu.co:2048/ehost/pdfviewer/pdfv....
  41. Lee SJ, Flowers MED. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008:134-41. Fecha de consulta: 22 de febrero de 2015. Disponible en: http://asheducationbook.hematologylibrary.org/content/2008/1/134.long.
  42. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn J-Y, et al. Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse. Blood. 2002;100:406-14. Fecha de consulta: 15 de julio de 2015. Disponible en: http://www.bloodjournal.org/content/100/2/406.long?sso-checked=true.
  43. Martin PJ. Biology of chronic graft-versus-host disease: Implications for a future therapeutic approach. Keio J Med. 2008;57:177-83.
  44. Wei J, Zhang Y, Xu H, Jin J, Zhang J. Atopic dermatitis-like presentation of graft-versus-host disease: A novel form of chronic cutaneous graft-versus-host disease. J Am Acad Dermatol. 2013;69:34-9.
  45. Cornejo CM, Kim EJ, Rosenbach M, Micheletti RG. Atypical manifestations of graft-versus-host disease. J Am Acad Dermatol. 2015;72:690-5.
  46. Carpenter PA, Kitko CL, Elad S, Flowers MED, Gea-Banacloche JC, Halter JP, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2015;21:1167-87. Fecha de consulta: 5 de febrero de 2016. Disponible en: http://www.sciencedirect.com/science/article/pii/S1083879115002244
  47. Hashemi A, Bahrololoumi Z, Khaksar Y, Saffarzadeh N, Neamatzade H, Foroughi E. Mouth-rinses for the prevention of chemotherapy induced oral mucositis in children: A systematic review. Iran J Pediatr Hematol Oncol. 2015;5:106-12. Fecha de consulta: 20 de febrero de 2016. Disponible en: http://www-ncbi-nlm-nih-gov.bdigital.ces.edu.co:2048/pmc/articles/PMC447....
  48. Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, Jackson G, et al. Organ-specific management and supportive care in chronic graft-versus-host disease. Br J Haematol. 2012;158:62-78. Fecha de consulta: 22 de marzo de 2015. Disponible en: http://web.b.ebscohost.com.bdigital.ces.edu.co:2048/ehost/pdfviewer/pdfv....
  49. Flowers MED, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125:606-15. Fecha de consulta: 29 de junio de 2015. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304105/.
  50. Ballester-Sánchez R, Navarro-Mira MÁ, de Unamuno-Bustos B, Pujol-Marco C, Sanz-Caballer J, Botella-Estrada R. The role of phototherapy in cutaneous chronic graft-vs-host disease: A retrospective study and review of the literature. Actas Dermosifiliogr. 2015;106:651-7. Fecha de consulta: 24 de julio de 2015. Disponible en: http://www.actasdermo.org/en/the-role-phototherapy-in-cutaneous/articulo....
  51. Ratcliffe N, Dunbar NM, Adamski J, Couriel D, Edelson R, Kitko CL, et al. National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: Scientific opportunities in extracorporeal photopheresis. Transfus Med Rev. 2015;29:62-70.
  52. Zhu L, Couriel DR, Chang C-H. The effect of extracorporeal photopheresis on T cell response in chronic graft-versus-host disease. Leuk Lymphoma. 2015;18:1-9.
  53. Velásquez MM. Inmunointervención: fotoféresis, radioféresis, vacunas con células dendríticas. Rev Asoc Colomb Alerg Asma Inmunol. 2001;10:77-84.
  54. Peñas PF, Fernández-Herrera J, García-Diez A. Dermatologic treatment of cutaneous graft versus host disease. Am J Clin Dermatol. 2004;5:403-16.
  55. Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: Results from a prospective, multicenter, phase II study. Haematologica. 2010;95:1935-42.
  56. Baird K, Comis LE, Joe GO, Steinberg SM, Hakim FT, Rose JJ, et al. Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(6):1083-90.
.
Rev Asoc Colomb Dermatol. 2016; 24: 2 (Abril-Junio), 78/144-145
Disseminated juvenile xanthogranuloma associated with insect bites
Rev Asoc Colomb Dermatol. 2016; 24: 2 (Abril-Junio), 141-143
Acquired trichorrhexis nodosa
Rev Asoc Colomb Dermatol. 2016; 24: 2 (Abril-Junio), 138-140
Subcutaneous Sweet syndrome associated to myelodysplastic syndrome
Rev Asoc Colomb Dermatol. 2016; 24: 2 (Abril-Junio), 135-137
Gorlin syndrome with metastatic basocelular carcinoma in treatment with vismodegib
Rev Asoc Colomb Dermatol. 2016; 24: 2 (Abril-Junio), 127-132
Cutaneous angiosarcoma associated with systemic sclerosis
Rev Asoc Colomb Dermatol. 2016; 24: 2 (Abril-Junio), 122-126
Primary psychiatric disorders in dermatology
Rev Asoc Colomb Dermatol. 2016; 24: 2 (Abril-Junio), 105-121
Cutaneous graft versus host disease
Rev Asoc Colomb Dermatol. 2016; 24: 2 (Abril-Junio), 90-102.
.
Rev Asoc Colomb Dermatol. 2016; 24: 2 (Abril-Junio), 88-89
Patch test results in patients with allergic contact dermatitis in Medellín, Colombia, 2006-2013
Rev Asoc Colomb Dermatol. 2016; 24: 2 (Abril-Junio), 81-87
.
Rev Asoc Colomb Dermatol. 2016; 24: 2 (Abril-Junio), 78/144-145
.
Rev Asoc Colomb Dermatol. 2016; 24: 2 (Abril-Junio), 76-77.

PATROCINADORES PRINCIPALES

  • MEDIHEALTH
  • SESDERMA
  • MD FARMACIA MAGISTRAL
  • EPIDERMIQUE
  • ISDIN
  • GALDERMA